Lifirafenib hydrochloride
Based on 3 publication(s) in Google Scholar
Lifirafenib hydrochloride (BGB-283 hydrochloride) is a novel, reversible B-RAFV600E inhibitor with antitumor activity. Lifirafenib has shown potent antitumor activity against solid tumors with B-RAFV600E mutations, such as melanoma, thyroid cancer, and low-grade serous ovarian cancer. Lifirafenib exhibits selective cytotoxicity in vitro, preferentially inhibiting the proliferation of cancer cells with B-RAFV600E and EGFR mutations/amplification. Lifirafenib can achieve dose-dependent inhibition of tumor growth in animal models, accompanied by partial and complete tumor shrinkage.
For research use only. We do not sell to patients.
- CAS No.: 2025320-97-0
- Formula: C25H18ClF3N4O3
- Molecular Weight:514.88
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Lifirafenib hydrochloride
MoreAll Endogenous Metabolite Isoforms
More
Biological Activity
Description
Chemical Information
-
CAS No. 2025320-97-0
-
Molecular Weight 514.88
-
Formula C25H18ClF3N4O3
-
SMILES
O=C1NC2=NC=CC(OC3=CC=C(O[C@@]4([H])[C@]5([H])[C@@H]4C6=NC7=CC=C(C(F)(F)F)C=C7N6)C5=C3)=C2CC1.Cl
-
Synonyms
BGB-283 hydrochloride
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
J Mol Med (Berl)
The role and mechanism of TNFRSF21 in promoting necroptosis of vascular endothelial cells and inducing vascular leakage in sepsis. [Abstract]2026 Apr 23;104(1):68. PMID: 42020785 -
J Med Virol
Small molecule RAF265 as an antiviral therapy acts against HSV-1 by regulating cytoskeleton rearrangement and cellular translation machinery. [Abstract]2023 Jan;95(1):e28226. PMID: 36251738 -
bioRxiv
A structure-based modelling approach identifies effective drug combinations for RAS-mutant acute myeloid leukemia. [Abstract]2025 May 3:2025.04.29.651188. PMID: 40654850
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Lifirafenib hydrochloride Related Classifications
HY-18957C Related Classifications
Powered by Bioz